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ORIGINAL CONTRIBUTIONSMeta-analysis of the effect of an essential
oil–containing mouthrinse on gingivitis and
plaqueABSTRACT
Background. Standard recommendations for oral hy-
giene practices have focused on mechanical methods
(toothbrushing and interdental cleaning). Published evi-
dence indicates antimicrobial mouthrinses provide oralMarcelo W.B. Araujo, DDS, MS, PhD;
Christine A. Charles, RDH, BS; Rachel B.
Weinstein, PhD; James A. McGuire, MS;
Amisha M. Parikh-Das, PhD, MPH; Qiong Du, MMS;
Jane Zhang, PhD; Jesse A. Berlin, ScD;
John C. Gunsolley, MS, DDShealth beneﬁts beyond mechanical methods alone. The
purpose of this meta-analysis was to evaluate the combined
effectiveness of mechanical methods with essential oil–
containing mouthrinses (MMEO) versus mechanical
methods (MM) alone in achieving site-speciﬁc, healthy
gingival tissue and reducing plaque and gingivitis.
Types of Studies Reviewed. All industry-sponsored
clinical trials investigating the antigingivitis and antiplaque
effects of essential oil (EO)–containing mouthrinses con-
ducted from 1980 to 2012 were reviewed; 29 of 32 studies
met the inclusion criteria of 6 months or longer duration,
randomized, observer-masked, placebo-controlled, and
with individual-level site-speciﬁc data. By-study treatment
effects were estimated through generalized linear models
for binary data and analysis of covariance for continuous
data, and then combined using standard meta-analysis
techniques; heterogeneity was also assessed.
Results. Summary odds ratios for a healthy gingival site
and for a plaque-free site were, respectively, 5.0 (95%
conﬁdence interval [CI], 3.3-7.5) and 7.8 (95%CI, 5.4-11.2)
for MMEO participants versus MM participants at 6
months. The summary percentage reductions in whole-
mouth mean gingivitis and plaque at 6 months were 16.0
(95% CI, 11.3-20.7) and 27.7 (95% CI, 22.4-32.9), respec-
tively. Responder analyses using aggregate individual-level
data showed 44.8% of MMEO participants and 14.4% of
MMparticipants achieved at least 50% healthy sites in their
mouths at 6 months. Similarly, 36.9% of MMEO partici-
pants and 5.5% of MM participants achieved at least 50%
plaque-free sites in their mouths at 6 months.
Conclusions and Practical Implications. This is the
ﬁrst meta-analysis to demonstrate the clinically signiﬁcant,
site-speciﬁc beneﬁt of adjunctive EO treatment in people
within a 6-month period (that is, between dental visits).
Key Words. Meta-analysis; antiplaque; antigingivitis;O ral health is integral to the general healthand well-being of patients.1-5 Althoughlargely preventable, oral disease is recog-nized to signiﬁcantly burden the economic,
psychological, and social development of commu-
nities across the globe.6 Gingivitis and other
periodontal diseases continue to exist as serious
challenges on a global scale. The Third National
Health and Nutrition Examination Survey
(NHANES) publication (NHANES III) reports
gingivitis prevalence to be 86% of the adult US
population,1 whereas studies in Latin America report
it to be as high as 100%7 and affecting over 95% of
adults in Southeast Asia.8 In the United Kingdom,
the Adult Dental Health Survey (2009) found that
54% of dentate adults had bleeding in the mouth,
which is a sign of gingival inﬂammation.9
Treatment and prevention of gingivitis are important
because, if left untreated, it can progress to more advanced
periodontal disease.5 Recommendations on oral hygiene
practices from dental practitioners have largely focused on
the mechanical methods of daily oral hygiene, including
toothbrushing and interdental cleaning as standards to
achieving and maintaining good oral health.10 However,
systematic reviews and meta-analyses have reported that
mouthrinses can provide a beneﬁt beyondmechanical oral
hygiene alone in preventing plaque accumulation and
gingivitis.3,10-12
Published and unpublished evidence was collected
by the sponsor (Johnson & Johnson Consumer Com-
panies) from 32 long-term randomized clinical trials
that totaled more than 5,000 healthy participants with
gingivitis for whom an essential oil (EO)–containingCopyright ª 2015 American Dental Association. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
oral hygiene; mouthrinse; essential oils.
JADA 2015:146(8):610-622
http://dx.doi.org/10.1016/j.adaj.2015.02.011
610 JADA 146(8) http://jada.ada.org August 2015
Studies included in some of the meta-analysis, 
but not all of the meta-analysis  (n = 29)
Studies found (n = 35)
 - Published studies sponsored by J&J (n = 17)
 - Published studies not sponsored by J&J (n = 3)
 - Unpublished studies sponsored by J&J (15)
Studies excluded from the meta-analysis (n = 6) because:
 - Published studies not sponsored by J&J did not have subject level data (n = 3)
 - Unpublished studies sponsored by J&J did not have available subject 
level data (n = 2)
 - Unpublished study sponsored by J&J did not include a marketed 
essential oil–containing mouthrinse (n = 1)
Figure 1. Study inclusion and exclusion criteria. J&J: Johnson & Johnson.
ORIGINAL CONTRIBUTIONSantimicrobial mouthrinse
(Listerine, Johnson &
Johnson) was used.13-41
These studies were
conducted for various
reasons, including
demonstrating efﬁcacy
of ﬂavor variants, investi-
gating modiﬁcations in
formula excipients
or process, examining ef-
ﬁcacy and safety compar-
isons with marketed
products, or evaluating
oral hygiene regimens in
comparison with me-
chanical methods.
All studies were
designed to meet the
commonly accepted pro-
fessional and regulatory
standards set by the
American Dental Asso-
ciation (ADA) and the US Food and Drug Adminis-
tration (FDA).42,43 The unpublished studies were not
previously made available to the general public as peer
review articles because some of them were imple-
mented either to support regulatory submissions, ap-
plications for a seal of acceptance, or for internal
knowledge. However, in the context of the recent
movement of biomedical science toward increased data
sharing, it is important that results from these long-
term studies are disclosed to the scientiﬁc community,
thereby contributing to evidence-based research in
dentistry.
The purpose of this meta-analysis was to compare the
degree of response to therapy (mechanical only versus
mechanical with essential oil mouthrinse use) toward
achieving gingival health. The primary objective was to
compare the efﬁcacy of combined mechanical oral hy-
giene and use of essential oils containing mouthrinses
with that of mechanical oral hygiene (negative control)
based on the percentage of healthy gingival sites identiﬁed
at 6 months. A second objective was to examine treat-
ment effects using other summary measures based on
the plaque index (PI). Lastly, we evaluated and reported
potential sources of heterogeneity of the treatment effect
as related to differences among studies and study results.ABBREVIATION KEY. ADA: American Dental Association.
B/F: Brushing and ﬂossing. DOF: Data on ﬁle. EO: Essential
oil. FDA: Food and Drug Administration. GI: Gingival index.
H: 5% Hydroalcohol control. J&J: Johnson & Johnson. MGI:
Modiﬁed gingival index. MM: Mechanical methods alone.
MMEO: Mechanical methods with essential oil–containing
mouthrinses. N: No. NHANES: National Health and Nutrition
Examination Survey. PI: Plaque index. SW: Sterile colored
water control. Y: Yes.METHODS
Individual study protocols were reviewed by each insti-
tutional review board committee at the time the indi-
vidual study was conducted. This meta-analysis protocol
was registered on PROSPERO (www.crd.york.ac.uk/
PROSPERO, registration number: CRD42013006356), aninternational prospective register of systematic reviews
and meta-analyses.
Types of studies included. Thirty-two clinical
studies, 6 months or longer duration, observer-masked,
parallel, randomized, placebo-controlled, sponsored by
Johnson & Johnson Consumer Companies and its pre-
decessors that assessed the effect of marketed mouth-
rinses containing the ﬁxed combination of 4 essential oils
on gingivitis and plaque were considered for this meta-
analysis. Twenty-nine studies met the inclusion criteria
for this meta-analysis as individual-level data were
required for both the site-speciﬁc measures in the
meta-analysis and in the responder analysis. Twenty-
nine studies were included in the gingivitis analyses, 27 of
those studies were included in the analysis of the primary
outcome variable, and 28 studies were included in the
plaque analyses. It is not clear if other researchers of
EO-containing mouthrinses have conducted 6-month
clinical trials according to the ADA guidelines. There-
fore, other trials of the intervention were not included, as
not all published 6-month trials adhered to the ADA
guidelines, utilized the modiﬁed gingival index (MGI),
included a placebo control, and most importantly, hadJADA 146(8) http://jada.ada.org August 2015 611
TABLE 1
Summary of study characteristics.
STUDY YEAR
STUDY
INITIATED
COUNTRY DENTAL
PROPHYLAXIS
SUPERVISED
RINSING
FLOSSING PLAQUE
INDEX NO.
SURFACE
NEGATIVE
CONTROL
RINSE OR
B/F*
MEAN
GINGIVITIS
INCLUSION
CRITERIA
MEAN
PLAQUE
INCLUSION
CRITERIA
Menaker &
Ross,13 1981
(DOF†)
1980 United
States
Y‡ Y N§ 2 V¶ 2.00 2.00
Lamster and
Colleagues,14
1983
1981 United
States
N Y N 6 V/SW# 2.00 1.80
Gordon and
Colleagues,15
1985
1981 United
States
Y Y N 2 V/SW 2.00 1.80
DePaola and
Colleagues,16
1989
1984 United
States
Y Y N 2 H** 1.95 1.95
Overholser and
Colleagues,17
1990
1987 United
States
Y Y N 2 H 1.95 1.95
Mankodi and
Colleagues,18
1989 (DOF)††
1988 United
States
Y Y N 2 H 0.95 1.95
Charles and
Colleagues19
(2004)††
1988 United
States
Y Y N 2 H 0.95 1.95
Mankodi and
Colleagues,20
1990 (DOF)
1990 United
States
Y Y N 2 H 1.95 1.95
Overholser and
Colleagues,21
1992 (DOF)
1991 United
States
Y Y N 2 V 1.95 1.95
Mankodi and
Colleagues,22
1993 (DOF)
1992 United
States
Y Y N 2 V 1.95 1.95
Sharma and
Colleagues,23
1997 (DOF)
1995 Canada Y Y N 2 H 1.95 1.95
Mankodi and
Colleagues,24
1997 (DOF)
1995 United
States
Y Y N 2 H 1.95 1.95
Charles and
Colleagues,25
2001
1997 Canada Y N N 6 H 1.75 1.75
Charles and
Vincent,26 1999
(DOF)
1998 United
States
Y N N 6 H 1.75 1.95
Sharma and
Colleagues,27
2002
2000 Canada Y N N 6 H 1.75 1.95
Barouth and
Colleagues,28
2003
2000 United
States
Y N N 6 H 1.75 1.95
Sharma and
Colleagues,29
2004
2002 Canada Y N Y 6 H 1.75 1.95
* B/F: Brushing and ﬂossing.
† DOF: Data on ﬁle.
‡ Y: Yes.
§ N: No.
¶ Vehicle control.
# SW: Sterile colored water control.
** H: 5% Hydroalcohol control.
†† Gingival index was used in these 2 studies.
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TABLE 1 (CONTINUED)
STUDY YEAR
STUDY
INITIATED
COUNTRY DENTAL
PROPHYLAXIS
SUPERVISED
RINSING
FLOSSING PLAQUE
INDEX NO.
SURFACE
NEGATIVE
CONTROL
RINSE OR
B/F*
MEAN
GINGIVITIS
INCLUSION
CRITERIA
MEAN
PLAQUE
INCLUSION
CRITERIA
Charles and
Peng,30 2009
(DOF)
2004 Canada
and United
States
Y N N 6 H 1.75 1.95
Charles,31 2012
(DOF)
2005 United
States
Y N N 2 H 1.75 1.95
Santos and
Colleagues,32
2006
2005 Canada Y N N 6 H 1.75 1.95
Santos and
Colleagues,33
2012
2006 Canada N N N 6 H 1.95 1.95
Charles and
Colleagues,34
2013
2007 United
States
N N N 6 H 1.75 1.95
Sharma and
Colleagues,35
2010
2008 Canada Y N N 6 H 1.75 1.95
Simmons and
Colleagues,36
2010
2008 United
States
N N Y 6 No
negative
control
rinse
1.75 1.95
Cortelli and
Colleagues,37
2012
2009 Brazil Y N N 6 H 1.75 1.95
Cortelli and
Colleagues,38
2013
2010 Brazil Y N N 6 H 1.75 1.95
Junker and
Colleagues,39
2012 (DOF)
2010 Canada N N N 6 H 1.75 1.95
Lynch and
Colleagues,40
2014 (DOF)
2010 Canada N N N 6 H 1.95 1.95
Cortelli and
Colleagues,41
2014
2012 Brazil Y N N 6 H 1.75 1.95
ORIGINAL CONTRIBUTIONSsite-level data available for external researchers to use
(Figure 1).
Treatments included. If a study included more than
1 mechanical methods (MM)-only group, only groups
having the same mechanical components as the me-
chanical methods with essential oil–containing mouth-
rinse (MMEO) group were included. The MMEO group
included the same mechanical methods and 20 milliliters
of EO mouthrinse, used twice daily for 30 seconds.
Inclusion criteria for original studies and data
extraction. Table 1 summarizes the protocol character-
istics for the included studies. The study populations
included generally healthy men and women, 18 years or
older, with at least 20 natural scorable teeth (teeth with
facial and lingual surfaces that were not grossly carious,
fully crowned, extensively restored, orthodontically
banded, acting as abutments, or were third molars). The
participants presented with mild to moderate levels of
gingival inﬂammation and dental plaque but withoutsigns of clinical periodontitis: MGI44 of 1.75 or greater, or
gingival index45 (GI) of 0.95 or greater and Turesky
Modiﬁcation of the Quigley-Hein Plaque Index46,47
(PI) of generally 1.95 or greater.
Outcomes. Analyses were deﬁned based on outcomes
or variables that determined the positive impact of the
treatments. They were chosen based on the clinical
relevance, which could help clinicians to better choose
a preventive approach.
Primary outcome.
-Healthy site (yes or no): A site was deﬁned as healthy
(yes) if MGI scores were 0 or 1 at 6 months. A site
was not deﬁned as healthy (no) if MGI scores were 2, 3, or
4 at 6months. Because the categorization of healthy sites as
MGI of 0 or 1 is not compatible with any categorization of
GI, the 2 studies using GI were excluded from the healthy
site analysis. AGI score of 1 is equivalent toMGI scores of 1
and 2, and therein lies the difﬁculty in combining the GI
with the MGI. The MGI affords an expansion of the scaleJADA 146(8) http://jada.ada.org August 2015 613
TABLE 2
Demographics and baseline characteristics across
studies (all randomized studies).
PARAMETERS MECHANICAL
ONLY
(N [ 2,562)
MECHANICALWITH
MOUTHRINSE USE*
(N [ 2,544)
TOTAL
(N [ 5,106)
Age, y
n 2,499 2,483 4,982
Mean (SD†) 34.7 (11.1) 34.6 (10.9) 34.6 (11.0)
Median 34.0 34.0 34.0
Minimum-Maximum (17-73) (17-74) (17-74)
Sex, n (%)
Male 930 (37.2) 956 (38.4) 1,886 (37.8)
Female 1,569 (62.8) 1,531 (61.6) 3,100 (62.2)
Race, n (%)
White 1,415 (72.5) 1,438 (72.0) 2,853 (72.2)
Nonwhite 538 (27.5) 560 (28.0) 1,098 (27.8)
Smoker, n (%)
Yes 485 (19.0) 443 (17.4) 928 (18.2)
No 2,072 (81.0) 2,100 (82.6) 4,172 (81.8)
Smokeless Tobacco Use, n (%)
Yes 1 (< 1.0) 0 1 (< 1.0)
No 951 (99.9) 996 (100) 1,947 (99.9)
Baseline Mean Modiﬁed
Gingival Index
n 2,478 2,462 4,940
Mean (SD) 2.2 (0.2) 2.2 (0.2) 2.2 (0.2)
Median 2.1 2.1 2.1
Minimum-Maximum (1.7-3.3) (1.7-3.1) (1.7-3.3)
Baseline Mean Gingival Index‡
n 84 80 164
Mean (SD) 1.3 (0.2) 1.3 (0.2) 1.3 (0.2)
Median 1.2 1.2 1.2
Minimum-Maximum (1.0-1.8) (1.0-1.8) (1.0-1.8)
Baseline Mean Plaque Index
n 2,503 2,488 4,991
Mean (SD) 2.8 (0.4) 2.8 (0.4) 2.8 (0.4)
Median 2.8 2.7 2.8
Minimum-Maximum (1.7-4.7) (1.8-4.4) (1.7-4.7)
Baseline % Healthy Sites
n 2,478 2,462 4,940
Mean (SD) 2.3 (3.7) 2.3 (3.7) 2.3 (3.7)
Median 0.0 0.0 0.0
Minimum-Maximum (0.0-30.8) (0.0-27.8) (0.0-30.8)
Baseline % Plaque-Free Sites
n 2,503 2,488 4,991
Mean (SD) 2.6 (5.5) 2.6 (5.5) 2.6 (5.5)
Median 0.0 0.0 0.0
Minimum-Maximum (0.0-43.2) (0.0-42.4) (0.0-43.2)
* Mouthrinse refers to marketed Listerine brand of ﬁxed combination of 4 essential oils.
† SD: Standard deviation.
‡ Gingival index only applies to Mankodi and colleagues18 and Charles and colleagues.19
ORIGINAL CONTRIBUTIONSat the lower end in order to reﬂect resolution of inﬂam-
mation from the complete unit being involved to only a
partial unit having inﬂammation.614 JADA 146(8) http://jada.ada.org August 2015Secondary outcomes.
- Percentage change in a partici-
pant’s whole-mouth mean gingivitis
score (MGI/GI) from baseline at
6 months.
- Plaque-free site (yes/no): A site
was deﬁned as plaque-free (yes) if PI
scores were 0 or 1. A site was not
deﬁned as plaque-free (no) if PI
scores were 2, 3, 4, or 5.
- Percentage change in a partici-
pant’s whole-mouth mean plaque
score (PI 2 or 6 surfaces) from
baseline at 6 months.
Data analysis. Meta-analysis. For
the analysis of healthy sites and
plaque-free sites, by-study treatment
effect and standard error (SE) esti-
mates were obtained using a gener-
alized linear model approach, using
a logit link based on the odds of
healthy or nonhealthy sites (or
plaque-free or plaque sites). A model
was ﬁt by study, including terms for
treatment and for baseline percentage
of healthy (or plaque-free) sites as a
covariate. This model was used to
estimate the odds ratio (OR) and
associated SE within each study.
The method of DerSimonian and
Laird48 was then used to generate a
pooled overall estimate of the OR
based on a random effects assump-
tion, using the estimates for the
within-study ORs and associated
SEs. The corresponding estimate
based on the ﬁxed effects assump-
tion was obtained similarly by
combining the within-study esti-
mates, using as weights the inverse
of the squared within-study SEs.
Forest plots were generated for
healthy sites and plaque-free sites,
with a conﬁdence interval (CI) for
each study, and an overall summary
OR, and percentage change.
For percentage change from
baseline in whole-mouth mean
gingivitis and plaque scores, ana-
lyses were based on a model with
percentage change at the participant
level as the response and baseline
mean score as a covariate. Themethod of DerSimonian and Laird48 was then used to
generate a pooled overall estimate of the between-
treatment differences based on the random effects
Study 
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n
85
129
127
109
83
146
116
82
144
134
225
204
212
158
238
239
236
236
132
248
116
254
208
138
149
230
205
OR
1.1
4.2
1.2
2.2
2.6
1.9
3.1
1.3
3.8
1.7
1.4
5.2
3.5
4.3
4.3
1.7
4.8
66.0
20.2
37.5
3.1
6.9
30.8
8.8
9.8
62.0
5.6
95% CI
0.7-1.9
3.1-5.6
0.8-1.9
1.5-3.2
1.6-4.2
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5.0 3.3-7.5
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Favors Mechanical With Mouthrinse Use
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5.5 5.1-5.8
Figure 2. Odds ratios (OR) and 95% conﬁdence intervals (CI) of whole-mouth healthy sites at month 6 intention-to-treat population. The years in
parentheses represent the dates that the studies were initiated. DOF: Data on ﬁle.
ORIGINAL CONTRIBUTIONSassumption, using the individual study estimates and
standard errors.
The statistical and clinical relevance of the speci-
ﬁc study characteristics, that is, heterogeneity, were
evaluated by exploring interactions between treatment
and the following study characteristics: 6- versus
2-surface plaque index (plaque-free sites and percentage
reduction in plaque), GI versus MGI (percentage
reduction in mean GI or mean MGI), supervised versus
unsupervised rinsing, dental prophylaxis versus nodental prophylaxis, ﬂossing versus no ﬂossing, study
period, and study location.
Responder analysis. A responder analysis was con-
ducted on the aggregated individual participant–level
data to evaluate individual participant responses, using
cumulative distribution of responder analysis graphs.49
This responder analysis approach presents the propor-
tion of responders over the entire range of possible cutoff
points, visually. This allows clinicians to compare treat-
ment groups at any response level that is valid for theirJADA 146(8) http://jada.ada.org August 2015 615
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Figure 3. Responder analysis of percentage reduction of whole-mouth mean modiﬁed gingival index (MGI) and gingival index (GI) (27 studies) and
whole-mouth plaque index (PI) (28 studies).
ORIGINAL CONTRIBUTIONSpatient population. This visual display accompanies the
analyses of percentage of healthy sites and percentage
of plaque-free sites. In the context of healthy sites, for
instance, the responder curve plots the proportion of
participants within each treatment group achieving at
least the given percentage of healthy sites, for all possible
percentages of healthy sites (0-100%).
Assessment of risk of bias. Risk of bias in each of
the included studies was evaluated per the principles
of the Cochrane Handbook for Systemic Reviews of
Interventions.50 All studies were randomized trials. Spe-
ciﬁcally, in this context, we evaluated whether these
studies were observer-masked and monitored after the
Good Clinical Practice quality standard based on the
International Conference on Harmonization guidelines
for clinical research. These clinical studies were care-
fully designed and they contain detailed individual
patient–level data including demography and baseline
characteristics, patient disposition, outcomes, and adverse
events.
RESULTS
Demography. The available demographic and baseline
characteristics are provided in Table 2. Data from a total
of 5,106 randomized participants were included in the
meta-analysis set, of which 2,562 participants received
MM treatment only and 2,544 participants received
MMEO treatment. The mean age of the study population
was 35 years, 72% of participants were white, 62% of
participants were women, and 18% of participants were
smokers (self-reported). Baseline clinical characteristics616 JADA 146(8) http://jada.ada.org August 2015for all randomized participants by treatment group are
provided in Table 2. Baseline means (standard de-
viations) for key clinical indexes assessed in the meta-
analyses were MGI ¼ 2.2 (0.2), GI ¼ 1.3 (0.2), PI ¼ 2.8
(0.4). There were no notable differences among treat-
ment groups for any of the demographic or baseline
characteristics.
Efﬁcacy. Efﬁcacy analyses were performed on the
intention-to-treat populations across 29 clinical studies
that ﬁt the criteria for the meta-analysis, including
4,827 participants with postbaseline data (2,425 in the
MM treatment group and 2,402 in the MMEO group).
The odds ratio of a healthy gingival site (27 studies)
for participants in the MMEO treatment group at 6
months was 5.0, compared with participants in the
control group (OR ¼ 5.0; 95% CI, 3.3-7.5), from the
random effects model (Figure 2). For the secondary
outcome variable, percentage reduction from baseline in
MGI/GI (n ¼ 29 studies) at 6 months, the summary
difference between percentage reductions and 95% CI
were 16.0 (11.3-20.7). Responder curves for percentage
reduction in whole-mouth mean MGI/GI and PI are
presented in Figure 3. Responder analysis results showed
that 66% of patients in the MMEO group and 24% pa-
tients in the MM group achieved a threshold of 20%
reduction in MGI/GI. The responder curves for per-
centage of whole-mouth healthy sites are presented
in Figure 4. Responder analysis results showed that for a
threshold of 50% healthy sites, 44.8% of MMEO subjects
and 14.4% of MM participants met this threshold
(Figure 4).
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Figure 4. Responder analysis of percentage of whole mouth-healthy sites (27 studies) and plaque-free sites (28 studies) intention-to-treat population.
ORIGINAL CONTRIBUTIONSTwenty-eight of the 29 studies were included for the
percentage of plaque-free sites (yes or no), because 1 study
had only partial data available due to unreadable case
reports. The summary OR of a plaque-free site
for participants in the MMEO group compared with par-
ticipants in the MM group, was 7.8 (95% CI, 5.4-11.2) from
the random effects model. The study-speciﬁc ORs and
conﬁdence intervals for plaque-free sites are presented in
Figure 5. For the variable percentage reduction from base-
line in PI at 6 months, the summary percent reductions
(95% CI) was 27.7 (22.4-32.9). Figure 3 provides the
responder curve for percent reduction in whole-mouth
mean PI, with 83% of MMEO participants achieving 20%
reduction in PI from baseline after 6 months, compared
with 25% of MM participants. Figure 4 provides the
responder curves for mean percentage plaque-free sites,
with 36.9%ofMMEOparticipants experiencing at least 50%plaque-free sites after 6months comparedwith 5.5%ofMM
participants.
Risk of bias in the original studies. Regarding
risk of bias, all studies were conducted using a
computer-generated randomization scheme with vary-
ing levels of ﬁxed block sizes depending on the study
size, all test products were administered by personnel
not involved in participant enrollment or study assess-
ments, and study test products were either group-coded
(early studies) or individually coded and randomized.
All 29 studies adhered to the same basic methodology
and were monitored after the Good Clinical Practices
and ICH guidelines for clinical research. There was a
low risk of performance and detection bias because the
key study personnel were masked to treatment assign-
ment across all studies. The dropout rate in all studies
was less than 10% and attrition was balanced across theJADA 146(8) http://jada.ada.org August 2015 617
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Figure 5. Odds ratios (OR) and 95% conﬁdence intervals (CI) of whole-mouth plaque-free sites at month 6 intention-to-treat population. The years in
parentheses represent the dates that the studies were initiated. DOF: Data on ﬁle.
ORIGINAL CONTRIBUTIONStreatment groups. All studies were funded by the
manufacturer; all protocols and reports were available;
all of the outcome variables (primary and secondary)
were prespeciﬁed in study protocols.
Heterogeneity assessment. Heterogeneity was exam-
ined by assessing the interaction between treatment and
each of the study characteristics separately. The study
characteristics examined were supervision, baseline618 JADA 146(8) http://jada.ada.org August 2015dental prophylaxis, ﬂossing, study period, and location.
In addition, we also considered—for the outcomes of
change in MGI/GI—which measure was used; and for
change in PI, the number of surfaces evaluated. Nearly
all of these interactions were statistically signiﬁcant and
were therefore sources of heterogeneity.
For study characteristics, study period, study location,
supervised rinsing, ﬂossing, prophylaxis, and 6- versus
TABLE 3
Summary of random effects measures according to whether studies included
ﬂossing or baseline dental prophylaxis as part of the mechanical regimen.*
END POINT FLOSSING
REQUIRED (CI)†
FLOSSING NOT
REQUIRED (CI)
PROPHYLAXIS
(CI)
NO PROPHYLAXIS
(CI)
Healthy Sites (Odds Ratio) 3.8 (2.7-5.2) 5.1 (3.3-8.0) 4.0 (2.5-6.4) 10.6 (4.3-26.1)
Percentage Reduction in Mean Gingival
Index/Gingival Index (MMEO Mean–MM Mean)
16.4 (12.3-20.5) 16.0 (11.0-21.0) 15.1 (9.7-20.5) 19.4 (8.0-30.9)
Plaque-free Sites (Odds Ratio) 11.1 (2.4-50.7) 7.6 (5.2-11.1) 6.5 (4.4-9.7) 17.0 (5.2-55.1)
Percentage Reduction in Plaque Index
(MMEO Mean–MM Mean)
34.6 (13.9-55.4) 27.1 (21.6-32.7) 26.8 (21.1-32.5) 30.8 (16.6-45.0)
* Random effects measures with 95% conﬁdence intervals.
† CI: Conﬁdence interval.
ORIGINAL CONTRIBUTIONS2-surface plaque were all closely related to each other.
All supervised rinsing studies occurred before all unsu-
pervised rinsing studies; study locations changed across
time, all but 1 of the 2-surface PI studies were conducted
before 1996 and all but 1 of the 6-surface studies were
conducted after 1996. Because of the correlation
among these characteristics, it is not clear whether the
improvement in results could be attributed to a subset of
these characteristics.
Treatment effects for plaque-free sites and percentage
change of PI differed by whether ﬂossing was part of the
regimen or not (Table 3). The other outcomes did not
differ by ﬂossing. Also, for all outcomes, the separation
between the MMEO and MM was larger for studies that
did not include a baseline dental prophylaxis (Table 3).
Therefore, the ORs for healthy sites and plaque-free sites
were larger for studies with no baseline dental prophy-
laxis than those with prophylaxis. Similarly, the per-
centage change of MGI/GI and of PI was larger for
studies without prophylaxis than those with a baseline
dental prophylaxis treatment.
DISCUSSION
Summary of evidence. In addition to the classical per-
centage reduction in plaque and gingival indexes, this
meta-analysis provides new information not only on
adjunctive use of mouthrinses containing essential oil
in achieving gingival health, but also relative to me-
chanical oral hygiene alone. All 32 long-term randomized
clinical trials (published and unpublished) sponsored
by the manufacturer were considered for inclusion in
the analysis; 29 met the inclusion criteria of the meta-
analysis protocol (one study did not contain a marketed
EO rinse and 2 studies did not have individual-level data
available).13-41 Though not as comprehensive as doing an
analysis of all potential studies, a meta-analysis of clinical
studies available to manufacturers has important bene-
ﬁts. It is important to highlight that because of regulatory
and ADA Seal of Acceptance requirements, these clinical
studies are carefully designed and executed, and they
contain detailed individual-level data including baselinecharacteristics, patient disposition, and outcomes. All
29 studies included in the meta-analysis were modeled
after the same basic methodology.42
This is the ﬁrst meta-analysis to perform a respond-
er analysis in which sites were evaluated regarding
presence and absence of disease, allowing the clinician
to evaluate the level of response the participants had
to treatment at 6 months. The rationale for daily
use of antiplaque/antigingivitis mouthrinses is twofold:
as an adjunctive component to mechanical oral hygiene
regimens29 for the control and prevention of plaque,
gingivitis, and dental caries,3 and as a method of deliv-
ering antimicrobial agents to mucosal sites throughout
the mouth that harbor potentially pathogenic bacteria
capable of recolonizing on supragingival and subgingival
tooth surfaces.51,52
In the 2006 meta-analysis by Gunsolley,11 3 marketed
mouthrinses containing chlorhexidine, cetylpyridinium
chloride, or EO were determined to have beneﬁcial anti-
plaque and antigingivitis effects when used long-term, and
in conjunction with other oral hygiene measures such as
brushing and ﬂossing.
A systematic review and meta-analysis published by
Van Leeuwen and colleagues12 in 2011 compared the
antiplaque and antigingivitis efﬁcacy of EO and other
mouthrinses, including 19 long-term studies that met the
inclusion criteria. The authors showed that EO mouth-
rinses appear to be a good choice for long-term use as
an antigingivitis agent. Finally, Gandini and colleagues53
and Boyle and colleagues3 presented quantitative as-
sessments of published data regarding use of mouthrinse
and risk of common oral conditions. Their analyses
focused on large epidemiologic studies and revealed that
there was a clear beneﬁt from use in terms of reducing
the risk of dental plaque, gingivitis, and caries and that
there were no major adverse effects. Speciﬁcally, they
found no statistically signiﬁcant association between use
of mouthwash containing alcohol and oral cancer risk.53
The present meta-analysis was designed to provide an
alternative method to interpret clinical data and pro-
pose a beneﬁt-based approach to clinical research andJADA 146(8) http://jada.ada.org August 2015 619
ORIGINAL CONTRIBUTIONSpractice, similar to what is applied in medicine, allowing
the clinicians to use the responder analyses and ORs to
evaluate the beneﬁt expected for their patients.48 This
methodology is presented in the FDA guidance on pa-
tient reported outcomes as a method for assessing indi-
vidual participant responses while avoiding the need to
pick a responder criterion.
The results of the responder analyses suggest that
after 6 months of use, clinicians could expect that
approximately 45% of patients would have at least 50% of
sites without gingivitis (MGI¼ 0 or 1) and approximately
37% of participants would have at least 50% of sites
without plaque (PI ¼ 0 or 1). In addition, the imple-
mentation of a long-term oral care routine that provides 7
times greater odds for plaque-free sites and 5 times greater
odds for healthy sites can be compelling information for
the clinician when educating patients on the appropriate
oral care routine.
Strengths and limitations. This is the ﬁrst meta-
analysis of long-term clinical data to include responder
analysis of published and unpublished results of the
beneﬁts provided by EO mouthrinses in achieving
gingival health in addition to mechanical methods of oral
hygiene. Because publication was not considered in the
inclusion of studies, this analysis is not subject to
publication bias. One of the limitations of the present
study involves the noninclusion of data from other
manufacturers and independent researchers, mostly
because the site-level data of other published data are not
publically available. However, to the best of our knowl-
edge, there are only 3 other published reports of EO
mouthrinses compared with placebo mouthrinses of
6 months duration that have been conducted by other
researchers.54-56 Those could not be included in the
current publication due to a lack of site-level and indi-
vidual participant-level data.
However, the meta-analysis presents a new approach
to clinical research data in dentistry, with focus on
achieving gingival health as a means of disease man-
agement. One of the main strengths shown here is the
fact that data developed from over 30 years of research
were generated by using the same clinical research
method applied to the protocols of all studies, generating
a unique database with over 5,000 participants, from
3 different countries, aged 18 years and older, both sexes,
and with other demographic characteristics that reﬂect
a diverse population.13-41
This analysis allowed for the identiﬁcation and
investigation of protocol differences and the exploration
of heterogeneity of the treatment effect, thereby helping
clarify the implications of any heterogeneity on the re-
sults. An implication of the analyses of heterogeneity
appears to be that the studies that more closely mimic
real world experience seem to produce larger estimates
of the beneﬁt of mouthrinses as part of daily oral
hygiene.620 JADA 146(8) http://jada.ada.org August 2015CONCLUSIONS
This meta-analysis of 6-month clinical trials supports the
clinically relevant beneﬁt of daily use of EO mouthrinses
for plaque and gingivitis reduction beyond MM oral
hygiene by determining the percentage of plaque-free
tooth surfaces and gingival sites that achieved health, the
goals of preventive services.
Addition of daily rinsing with an EO mouthrinse to
mechanical oral hygiene provided statistically signiﬁcantly
greater odds of having a cleaner and healthier mouth,
which may lead to prevention of disease progression.
Clinicians may ﬁnd this novel format of data representa-
tion for a range of responses helpful in reaching decisions
to manage plaque and gingivitis for all patients. n
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